Salofalk, which contains mesalazine, is commonly used to help with conditions characterized by periods of heightened symptoms, specifically ulcerative colitis (UC). Its primary therapeutic role is applied in addressing both active disease and for maintaining periods of improvement. This is relevant for easing symptoms related to inflammatory or irritative states that affect the colon and rectum.

The medicine is considered relevant for managing episodes where symptoms become temporarily overwhelming, and is applied when functional stability becomes affected during maintenance phases.

Quick Fact: Supports Easing Inflammatory States

This medication contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

“It is generally applied in scenarios where additional management of discomfort is required.”

The use of mesalazine may assist with maintaining a sense of stability when symptoms are more noticeable, providing supportive relief when symptoms interfere with routine activities, and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus overview on Mesalamine

Eligibility Map: Who can and cannot use Салофальк (Mesalazine)

This section outlines the officially documented eligibility and non-eligibility criteria for Салофальк (Mesalazine) as defined by government regulatory agencies.

---

Eligibility scope	Classification of Use
Populations allowed	Adults (18 years and older) and children 6 years and older (for established indications and specific formulations).
Populations contraindicated	Patients with known hypersensitivity to mesalazine or any salicylates (like aspirin).
Organ function	Contraindicated in severe renal impairment and severe hepatic impairment.
Age-related rules	Use is not recommended in children under 6 years due to insufficient data. Older adults require close monitoring, especially of kidney function.
Pregnancy/Lactation	Use requires caution and is generally limited to cases where the benefit outweighs the possible risk, as stated in the label. The infant must be monitored if used during breastfeeding.

---

Official Eligibility Statements

The regulatory profile dictates that use is contraindicated for patients with a known allergy to salicylates or the active substance itself. It is also contraindicated in patients with severe compromise of liver or kidney function. Use in individuals with mild to moderate renal or hepatic impairment, pre-existing pulmonary disease (e.g., asthma), or active peptic ulceration requires special caution and monitoring. These classifications define the strict boundaries of who can and who cannot use the medicine under labeled conditions.

Interactions with other medicines and products

The interaction profile of Mesalazine (Salofalk) is formally documented by regulatory authorities, focusing on combinations that require special monitoring or pose an increased risk of toxicity.

Documented Interaction Patterns

Interacting Substance/Class	Officially Documented Outcome
Immunosuppressants (e.g., Azathioprine, 6-Mercaptopurine)	Increased risk of myelosuppression (blood disorders) due to possible inhibition of the TPMT enzyme.
Nephrotoxic Agents (e.g., NSAIDs)	Increased risk of renal adverse reactions (nephrotoxicity) via an additive pharmacodynamic effect.
Coumarin-type Anticoagulants (e.g., Warfarin)	Possible potentiation or attenuation of the anticoagulant effect, requiring close monitoring of clotting parameters.

Interaction-Related Requirements

Co-administration with thiopurines and nephrotoxic agents requires close and continuous monitoring of blood cell counts and renal function, respectively, as mandated by official labeling. Certain oral formulations require administration to be separated from preparations that lower the intestinal pH (e.g., Lactulose) to prevent premature drug dissolution and ensure proper Mesalazine release. For patients with existing renal impairment, the risk of the interaction with nephrotoxic agents is officially noted as more clinically significant. Mesalazine is also documented to cause spuriously elevated results in specific laboratory tests for urinary normetanephrine.

The action of Salofalk (Mesalazine) is localized and multi-targeted, centered on suppressing chronic inflammation directly at the intestinal mucosa. The molecule affects several distinct critical steps of the inflammatory process rather than acting on a single isolated target.

Modulation of Signaling and Enzyme Activity

Mesalazine acts as a modulator of central nuclear regulators, interfering with the activation of NF-kappa B to prevent the genetic transcription of pro-inflammatory cytokines. Simultaneously, the compound inhibits the enzymes 5-Lipoxygenase and Cyclooxygenase within the Arachidonic Acid Cascade, resulting in a reduced synthesis of chemical mediators, including LTB4 and PGE2. This combined mechanism contributes to a reduction of inflammatory cascade activity at the cellular level.

️ Neutralization of Toxic Radicals

Mesalazine exhibits antioxidant properties, enabling it to function as a scavenger of Reactive Oxygen Species (ROS) and free radicals released by immune cells. This direct chemical neutralization limits oxidative damage to cells and contributes to the maintenance of the structure of the mucosal barrier. The efficacy of this mechanism is critically dependent on achieving high local concentration in the target area, which is facilitated by minimal systemic absorption.

How to Use Salofalk: Administration Guidelines

Salofalk (mesalazine) administration is based on two primary pathways: the oral route (tablets or granules) and the rectal route (suppositories, enema, or foam). The choice of administration route depends on the extent of disease within the bowel, and all treatment must be used regularly and consistently.

Administration Patterns and Dosing

Clinical Phase	Dosing Range (Adults)	Frequency Pattern	Typical Duration
Acute Treatment	1.5 g to 3.0 g daily (oral)	Once daily (OD) or divided into three doses (TID)	Typically 8 weeks
Maintenance Treatment	1.5 g daily (oral)	Once daily or divided doses	Long-term, consistent use
Rectal Treatment	1 g suppository or 4 g enema daily	Once daily, preferably at bedtime	Variable (e.g., 3-6 weeks)

Specific Intake Requirements

Oral gastro-resistant tablets must be swallowed whole and not chewed or crushed to ensure the mesalazine is released in the lower bowel. Tablets should be taken 1 hour before meals with plenty of fluid. Similarly, the prolonged-release granules should be poured onto the tongue and swallowed whole without chewing.

Pediatric Dosing Principle

For children aged 6 years and older, oral dosing is individualized based on body weight. For active disease, the starting dose is typically 30–50 mg/kg/day in divided doses, not to exceed the adult maximum dose. For maintenance, the dose is 15–30 mg/kg/day. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose; do not double the dose.

Overview of Studies and Evidence Structure for Salofalk

---

1. Evidence for Use in Active Intestinal Inflammation

Research was studied for mesalazine in short-term clinical trials, mainly Randomized Controlled Trials (RCTs), conducted during periods of heightened symptom activity in adults with mild-to-moderate ulcerative colitis. These studies included comparisons against an inactive treatment (placebo) to examine outcomes related to physical discomfort and episodic changes linked to inflammatory states. The evidence contributes to the broader evidence landscape that regulatory bodies use to define treatment indications for this agent.

Data for certain groups, such as those with severe, extensive ulcerative colitis, remain insufficient to draw conclusions about the research scenario explored. Furthermore, the short follow-up durations used in these specific trials mean that long-term outcomes of the initial treatment phase are not fully established by this body of work.

---

2. Evidence for Maintaining Periods of Remission

Research explored scenarios focusing on periods of stability and flare-ups over defined time intervals. The central outcomes monitored included the relapse-free rate and the time interval until a flare-up occurred. Findings describe patterns observed in the studies in which continuous use was observed during periods of stability in the disease.

Research highlights that patterns of patient adherence (taking the medication consistently) was associated with monitored changes in outcomes reflecting daily functioning. The evidence contributes to understanding symptom patterns over the long term and contributes to the evidence landscape referenced by major guideline bodies.

---

3. Research in Special Patient Populations and Gaps

Dedicated research was studied for children and adolescents (pediatric populations) with mild-to-moderate ulcerative colitis. These pediatric trials monitored outcomes using special assessment tools specific to younger patients and examined outcomes related to growth and development. This research provides insight into treatment patterns for younger patients, but the overall volume of long-term evidence in this specific age group is limited compared to the adult research base.

Additionally, observational cohort studies extending over many years describe patterns related to the risk of developing colorectal cancer. However, this evidence is limited because it comes predominantly from observational settings; research provides context but not individual predictions and certainty regarding this specific outcome remains low due to the nature of the research design.

Key Studies & References

1. WHO Model List of Essential Medicines – 23rd list (2023) Explanatory notes
2. The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis
3. Mesalamine: MedlinePlus Drug Information

Common questions about Салофальк (FAQ)

Q: Can Салофальк be used for conditions other than ulcerative colitis?

According to official product labeling, Salofalk is indicated specifically for the treatment of acute episodes and the maintenance of remission in Ulcerative Colitis (UC). While it is an anti-inflammatory agent used for chronic bowel issues, it is not typically labeled for use in other distinct inflammatory bowel conditions, such as Crohn's Disease.

Q: Is Салофальк a steroid or a biologic drug?

Салофальк belongs to the Aminosalicylate class of medications, with the active ingredient being mesalazine (5-ASA). It is classified as an intestinal anti-inflammatory agent, meaning its action is primarily local in the gut. Regulatory information confirms that this medicine is distinct from both steroids and biologic therapies.

Q: Are there common skin reactions associated with Салофальк?

Official product information lists rash and itchy skin as potential side effects of mesalazine. In some regulatory documents, rash is classified as a common side effect, meaning it may affect up to 1 in 100 people. Regulatory documents indicate the importance of observing any changes to the skin during treatment.

Q: What are the signs of a serious reaction to Салофальк?

Serious adverse reactions can occur, though rarely. Official labeling indicates that signs such as severe headache, fever, acute abdominal cramps, or a significant rash may signal a hypersensitivity reaction (known as acute intolerance syndrome). Regulatory guidance indicates that if such signs occur, discontinuation of the medication and immediate consultation with a healthcare professional are warranted.

Q: What happens if I stop taking Салофальк suddenly?

Official administration guidelines emphasize that this medicine must be used regularly and consistently, particularly when prescribed for maintenance of remission. Regulatory research supports the role of treatment adherence in maintaining disease stability. Stopping the medication suddenly may increase the likelihood of the inflammatory condition returning or worsening (relapse).

Q: Is it normal to see tablet residue in stool after using Салофальк?

Due to the design of the oral formulations, which include a special coating for delayed release, it is possible to observe the empty shell or residue of the tablet in the stool. This occurs because the active medicine has been absorbed by the body, leaving behind the inert coating. This may be reported as a common finding for this type of gastro-resistant medication.

Q: Does Салофальк come with a patient information leaflet, and what does it emphasize?

As required by regulatory authorities, Салофальк is dispensed with a Patient Information Leaflet (PIL) or Medication Guide. This document provides essential details on how to use the medicine safely, clarifies the recognized side effects, and emphasizes important warnings and precautions for users.

Q: What are the long-term known effects of using mesalazine drugs like Салофальк?

Regulatory documents mandate that long-term use requires periodic monitoring of key health parameters, specifically kidney function and blood cell counts. Additionally, observational studies related to the mesalazine class have investigated patterns regarding the risk of colorectal cancer, providing important context for chronic disease management.

Q: Does Салофальк help with joint pain that sometimes happens with inflammatory bowel disease?

The primary function of Salofalk is to provide a localized anti-inflammatory effect directly to the bowel wall. It is not indicated for treating extra-intestinal manifestations of IBD, such as joint pain. Furthermore, official documentation lists arthralgia (joint pain) and myalgia (muscle pain) as potential side effects of the medication itself.

Q: Are eye problems listed as a possible side effect of Салофальк?

Official product labels for mesalazine formulations occasionally list eye problems, such as visual disturbance or conjunctivitis, typically classified as rare side effects. Regulatory guidance notes that the occurrence of disturbed vision warrants immediate discussion with a healthcare provider.

Q: Can Салофальк affect fertility in men or women?

Official regulatory guidance suggests there is no evidence that mesalazine reduces fertility in women. For men, some regulatory sources note rare, reversible reports of oligospermia (low sperm count) associated with the drug. This effect is generally reported to resolve upon discontinuation of the medicine.

Q: Does Салофальк contain any gluten or common allergens?

The presence of common allergens or excipients like gluten depends on the specific formulation and dosage form. Official labeling details the excipients, and some products may contain substances like aspartame or sodium benzoate. For patients with specific allergies or conditions, consulting the detailed excipient list in the patient leaflet for their specific product is indicated.

Q: Why is mesalazine sometimes prescribed in combination with other IBD medications?

Mesalazine is sometimes used alongside other IBD medications, such as certain immunosuppressants (like azathioprine or 6-mercaptopurine), to manage complex disease scenarios. Regulatory documents acknowledge this combined therapeutic approach by specifically detailing the required monitoring, particularly due to an increased risk of blood disorders (myelosuppression) associated with the drug interaction.

Q: What are the typical signs that Салофальк is working for a patient?

The primary objective of Salofalk is to reduce the chronic inflammation in the bowel. Official sources describe the treatment goal as achieving and maintaining remission, which correlates with observable symptom reduction. This typically means a decrease in symptoms such as bloody diarrhea, abdominal pain, and rectal bleeding.

How to Store and Dispose of Salofalk (Mesalazine)

Storage and disposal instructions for Salofalk are defined by regulatory labeling to ensure product stability and safety. All formulations must be kept out of the sight and reach of children.

Storage Conditions

Dosage Form	Temperature and Protection Requirements
Tablets & Enema	Store below 25 C; protect from light and moisture.
Suppositories	Store below 30 C; protect from light.
Rectal Foam	Store between 15 C and 30 C. Do not refrigerate or freeze.

All forms must be stored in the original container or package. The rectal foam container must also be kept tightly closed.

Disposal

Unused or expired Salofalk product and waste material must be disposed of in accordance with local requirements. This instruction requires disposal to follow recommendations governing pharmaceutical waste, meaning the product should not be placed in household waste or flushed down the toilet.